SCHEMBL12779412

SCHEMBL12779412

Cc1ccc(C(=O)Nc2cccc(CO)c2)c([N+](=O)[O-])c1OCc1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SENP5 Q96HI0 5/20 0.49
▸ SENP2 Q9HC62 5/20 0.49
▸ SENP1 Q9P0U3 5/20 0.49
▸ MEN1 O00255 8/20 0.49
▸ KMT2A Q03164 8/20 0.49
▸ MAPT P10636 4/20 0.48
▸ ALDH1A1 P00352 2/20 0.48
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ LRRK2 Q5S007 1/20 0.46
▸ ABCG2 Q9UNQ0 1/20 0.45
▸ LMNA P02545 1/20 0.44
▸ SIRT2 Q8IXJ6 1/20 0.43
▸ SIRT1 Q96EB6 1/20 0.43
▸ SIRT3 Q9NTG7 1/20 0.43
▸ SGMS2 Q8NHU3 1/20 0.43
▸ MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14199913 0.90 MEN1 (0.53) SENP5SENP2SENP1MEN1KMT2A
SCHEMBL12779413 0.88 MEN1 (0.47) SENP5SENP2SENP1MEN1KMT2A
SCHEMBL14199904 0.82 MEN1 (0.52) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL14228206 0.82 SENP5 (0.49) SENP5SENP2SENP1MEN1KMT2A
SCHEMBL12253970 0.81 PTPN1 (0.47) MEN1KMT2AMAPTSMN1; SMN2
SCHEMBL14199914 0.79 HPGD (0.47) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL14450789 0.77 HPGD (0.47) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL12253971 0.77 ALDH1A1 (0.46) KMT2AMAPTALDH1A1RAB9AMAPK1
SCHEMBL14199912 0.76 HPGD (0.46) MEN1KMT2AMAPTALDH1A1SMN1; SMN2
SCHEMBL12778249 0.75 MEN1 (0.47) MEN1KMT2AMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778874-B2 Glycopeptide antibiotic monomer derivatives NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2014-07-15 — — US disclosed
US-8778874-B2 Glycopeptide antibiotic monomer derivatives NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) 2014-07-15 — — US disclosed
EP-2314599-A1 Glycopeptide antibiotic monomer derivatives National University Corporation Nagoya University (JP) 2011-04-27 — — EP disclosed
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria SHIONOGI & CO., LTD. (JP) 2008-04-24 — — US disclosed
EP-1818340-A1 GLYCOPEPTIDE ANTIBIOTIC MONOMER DERIVATIVES National University Corporation Nagoya University (JP) 2007-08-15 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080097078-A1 Antibacterial activity against vancomycin-resistant bacteria CSGALNACT1, MON2, NR2C2 SENP5 2454/4885SENP2 1554/4885SENP1 1849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback